Docket Number: ENP-035

Applicant Serial Number : Wang et al. : 10/007,342 : October 22, 2001

Page

: 2

## Amendments to the claims:

## Claims 1-25 (Cancelled)

26. (Previously Added) A compound of the formula:

## wherein:

R<sup>1</sup> is chosen from the group consisting of  $C_1$ – $C_{20}$  alkyl, aryl, alkylaryl, substituted alkylaryl,  $C_1$ – $C_{10}$  alkoxy,  $C_1$ – $C_{10}$  oxaalkyl, aryloxy, substituted aryl, substituted aryloxy, heterocyclyl and heterocyclyloxy;

 $R^2$  is chosen from the group consisting of  $C_1$ - $C_{10}$  hydrocarbon, substituted aryl and heterocyclyl;

A is chosen from the group consisting of a direct bond, -SO<sub>2</sub>-, NHSO<sub>2</sub>-,

Docket Number: ENP-035

Applicant Serial Number : Wang et al. : 10/007,342 : October 22, 2001

Filed Page

. 3



is thiazolidine;

R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are chosen from the group consisting of hydrogen and lower alkyl;

- D is chosen from the group consisting of -SO<sub>2</sub>-; and
- E is chosen from the group consisting of  $C_1$ - $C_{10}$  hydrocarbon, substituted aryl, heterocyclyl and substituted heterocyclyl.
- 27. (Previously Added) A compound according to claim 26 wherein E is chosen from aryl, heteroaryl, substituted aryl and substituted heteroaryl.
- 28. (Cancelled) A method of treating or preventing a protease precipitated disease which comprises administering to a mammal suffering from said disease or at risk to said disease a therapeutically effective amount of a compound according to claim 26.
- 29. (Cancelled) A method according to claim 28 wherein said disease is HIV, AIDS, or a related condition.
- 30. (Cancelled) A method according to claim 28 wherein said disease is malaria.
- 31. (Cancelled) A method according to claim 28 wherein said disease is chosen from connective tissue disease, muscular dystrophy, breast cancer and Alzheimer's disease.
- 32. (Previously Added) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 26, or a pharmaceutically acceptable salt or solvate thereof.
- 33. (Previously Added) A pharmaceutical composition according to claim 32 comprising at least one additional antiviral agent.